We spoke to Professor Hugh Calkins (Nicholas J. Fortuin M.D. Professor of Cardiology, Director, Electrophysiology Laboratory and Arrhythmia Service, Johns Hopkins Hospital, Baltimore, MD, USA) at Heart Rhythm 2019 about upcoming developments in atrial fibrillation (AF) ablation and his thoughts on the use or the discontinuation of anticoagulants in patients without recurrence after AF ablation.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Hugh Calkins is a consultant for and has received honoraria from Biosense Webster, Medtronic, Abbott, Boston Scientific and Boehringer Ingelheim.
1. What developments should we expect to see in atrial fibrillation (AF) ablation over the next few years? (0:09)
2. What are your thoughts on the use versus the discontinuation of anticoagulants in patients without recurrence of disease after AF ablation? (0:53)
3. What are your key take-home messages from Heart Rhythm 2019? (2:02)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with Arrhythmia Alliance.
Share this Video
Related Videos In Atrial Fibrillation
Anthony Tang, ACC 2021: Findings from the RAFT-AF Trial
It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021. Abstract Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus […]
Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!